To evaluate the efficacy of a fixed-dose amlodipine (5 mg) and lisinopril (20 mg) association (FDA) over an 8 week treatment period, in grade II/III hypertensive patients evaluated with ambulatory blood pressure monitoring (ABPM).Objective:
Table 1. Variation of the office and ambulatory blood pressure.Design and method:
Thirty non-medicated patients (36% females) with grade II or III hypertension were included in an observational study. Mean age was 52.44+11:54 years, mean body mass index was 28.73+4.31 kg/m2, and mean office systolic (SBP) and diastolic (DBP) blood pressures were 174.43+15.06 mmHg and 102.83+10.67 mmHg, respectively. All patients underwent 24 hours ABPM at baseline and 8 weeks after initiating the treatment with the FDA. Office BP, blood and urine analytical parameters were also evaluated.Results:
Significant reductions in ambulatory BP were depicted after 8 weeks of treatment with the FDA (cf. table). Simultaneous normalization of ambulatory SBP and DBP over the three measurement periods (24 hours, day and night) was achieved in 69% of the patients, and office BP was normalized in 79%. For laboratory parameters, there was a significant reduction of microalbuminuria (reduction of 37.40 mg/24 h; CI: 2.82–71.97; p = 0.035), and fasting glucose (decreased 11.53 mg/dl; CI: 3.46–19.61; p = 0.007). No side effects were observed during the study.Conclusions:
An 8 weeks treatment with a FDA of 5 mg Amlodipine and 20 mg Lisinopril, was very effective in controlling a clinical population of moderate to severe hypertensive patients, with additional evidence that this efficacy can be achieved quickly, safely and is well tolerated.